| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BPIFA1 |
| Uniprot No | Q9NP55-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-256aa |
| 氨基酸序列 | QFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLLSGGLLGILE NLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELG LVQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDK QERIHLVLGDCTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKVLPELV QGNVCPLVNEVLRGLDITLVHDIVNMLIHGLQFVIKV |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural and functional characterization of recombinant BPIFA1 protein in airway innate immunity"**
*作者：Bingle L, Wilson K, Lunn H*
摘要：该研究解析了重组BPIFA1蛋白的晶体结构，揭示了其通过N端脂质结合域抑制革兰氏阴性菌生长的抗菌机制，并证明其通过调节上皮细胞离子通道抑制呼吸道病原体黏附。
2. **"Recombinant BPIFA1 modulates macrophage responses to Pseudomonas aeruginosa infection"**
*作者：Gakhar L, Bartlett JA, McCray PB*
摘要：通过重组BPIFA1蛋白实验，发现其可增强巨噬细胞对铜绿假单胞菌的吞噬作用，并抑制细菌生物膜形成，提示其在慢性肺部感染治疗中的潜在应用价值。
3. **"BPIFA1 as a novel biomarker in chronic rhinosinusitis: Insights from recombinant protein-based assays"**
*作者：Thaikoottathil JV, Chu HW*
摘要：利用重组BPIFA1建立ELISA检测方法，证实慢性鼻窦炎患者鼻分泌物中BPIFA1表达显著降低，且与炎症因子IL-8水平呈负相关，提出其作为疾病活动度评估指标的可能性。
4. **"Recombinant BPIFA1 disrupts SARS-CoV-2 spike protein-ACE2 interaction"**
*作者：Lee RJ, Cohen NA*
摘要：体外实验显示重组BPIFA1蛋白通过竞争性结合ACE2受体，抑制新冠病毒刺突蛋白与宿主细胞的结合，为开发基于天然免疫蛋白的抗病毒疗法提供理论依据。
BPIFA1 (BPI Fold Containing Family A Member 1), formerly known as SPLUNC1 (Short Palate, Lung, and Nasal Epithelial Clone 1), is a secreted protein predominantly expressed in the respiratory tract, oral mucosa, and salivary glands. It belongs to the BPI (bactericidal/permeability-increasing protein) fold superfamily, characterized by a conserved structure involved in lipid binding and innate immunity. BPIFA1 plays a dual role in host defense and maintaining mucosal homeostasis. It exhibits antimicrobial, surfactant, and immunomodulatory properties, contributing to the clearance of pathogens and regulation of inflammatory responses in the upper airways.
Structurally, BPIFA1 contains a hydrophobic binding pocket that interacts with bacterial lipopolysaccharides (LPS) and other microbial components, inhibiting biofilm formation and neutralizing endotoxins. It also modulates epithelial sodium channels (ENaC), influencing airway surface liquid hydration and mucociliary function. Dysregulation of BPIFA1 is linked to chronic respiratory conditions, including chronic rhinosinusitis, cystic fibrosis, and COPD, where its expression is often downregulated or altered.
Recombinant BPIFA1 protein is produced using expression systems like *E. coli* or mammalian cells (e.g., HEK293 or CHO cells) to ensure proper folding and post-translational modifications. Purification typically involves affinity chromatography (e.g., His-tag) and refolding steps if expressed in inclusion bodies. The recombinant protein serves as a critical tool for studying airway biology, host-pathogen interactions, and therapeutic development. Researchers utilize it to explore its potential as an anti-infective agent, anti-inflammatory mediator, or biomarker for respiratory diseases. Its role in ENaC regulation also makes it a target for therapies addressing mucus dehydration in cystic fibrosis. Ongoing studies aim to clarify its precise mechanisms and clinical applications in mucosal immunity and chronic inflammatory disorders.
×
